Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.

Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials.

The company is developing a novel duodenal mucosal resurfacing technology designed to reverse the metabolic process that causes insulin resistance in people with type 2 diabetes.

BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.